Global Tamiflu (Oseltamivir) Drug Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Tamiflu (Oseltamivir) Drug Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Tamiflu (Oseltamivir) Drug is an antiviral drug, a neuraminidase inhibitor, which can treat or prevent influenza A virus and influenza B virus.

Market Overview:

The latest research study on the global Tamiflu (Oseltamivir) Drug market finds that the global Tamiflu (Oseltamivir) Drug market reached a value of USD 788.93 million in 2022. It’s expected that the market will achieve USD 1269.45 million by 2028, exhibiting a CAGR of 8.25% during the forecast period.

Market Trends

At present, the main product dosage forms on the market include Capsule and Oral Solution. With the continuous development of the market with the Tamiflu (Oseltamivir) Drug industry market, industry companies have strengthened their research on new product formulations. For example, industry companies intensify research on dry suspension products. Dry suspension refers to a liquid preparation in which a poorly soluble drug and suitable excipients are made into powder or granule, which can be dispersed into a suspension for oral administration by adding water and shaking. Dry suspensions have the characteristics of solid preparations, such as easy portability, convenient transportation, good stability, etc., and the advantages of liquid preparations that are convenient to take. Relevant data show that compared with capsules, dry suspension Tamiflu (Oseltamivir) Drug has obvious clinical value and advantages for special populations with dysphagia. Compared with granules, it has unique taste masking and taste modification. Advantages, pediatric patients have better compliance. The Tamiflu (Oseltamivir) Drug product of dry suspension has advantages in the treatment of infants and young children. Under the specifications of 6mg/ml and 12mg/ml, it can flexibly meet the dosage requirements of pediatric patients of different weights. This type of product is equipped with a graduated measuring cup and an oral applicator, which is convenient for patients to accurately measure the water for preparation and take the medicine accurately, realize the flexible adjustment of the dosage, and achieve the goal of strict and accurate dosage. On October 26, 2020, the first oseltamivir phosphate dry suspension (Ovipin®) was approved by the NMPA in China, and it has also been approved by the US FDA for marketing. In general, with the continuous expansion of the Tamiflu (Oseltamivir) Drug market size and the increasingly fierce competition in the industry, industry companies continue to strengthen product formulation research. Products in the form of dry suspension will be one of the trends in the industry.

Challenges

The Tamiflu (Oseltamivir) Drug industry belongs to the pharmaceutical industry. The pharmaceutical industry is an industry directly related to national life safety and physical fitness level. Governments of various countries have always implemented very strict access and supervision systems for this industry. In the United States, the research and development, production, and marketing of Tamiflu (Oseltamivir) Drug are subject to US food and drug supervision. In Europe, the research and development, production, and marketing of Tamiflu (Oseltamivir) Drug are regulated by the European Medicines Agency. In China, all production links of Tamiflu (Oseltamivir) Drug are strictly regulated by the State Food and Drug Administration. Pharmaceutical manufacturing enterprises must obtain the Drug Production License, their products must have a drug registration approval document, the drug production conditions must pass the national GMP certification, and the circulation and operation of pharmaceutical commodities must pass the GSP certification. In general, due to the special behavior of the pharmaceutical industry, companies in the Tamiflu (Oseltamivir) Drug industry face strict government agency supervision and high barriers to entry in the industry. Strict government regulation is one of the challenges facing companies in the industry.

Region Overview:

In 2021, the share of the Tamiflu (Oseltamivir) Drug market in North America stood at 45.84%.

Company Overview

HEC Pharm
HEC Pharm was established in 2002. After more than ten years of development, HEC Pharm has become one of the pharmaceutical companies in China with independent innovation capability and development prospects. In 2006, HEC Pharm obtained Roche's patent license for oseltamivir in China (invention patent, patent number: ZL96190133.0, ZL2004800064811), HEC Pharm is currently the largest oseltamivir manufacturer in China. So far, all the production bases of HEC Pharm have passed the GMP certification of China, the United States and the European Union, and a batch of APIs and preparations have passed the official European Union and the United States FDA approval. Shareholders of HEC Pharm changed. The shareholding ratio of Shenzhen East Sunshine Health Pharmaceutical Co., Ltd. decreased from about 55.24% to about 53.731%, and the shareholding ratio of North and South Brothers Pharmaceutical Investment Co., Ltd. decreased from about 22.75% to about 22.13%. The shareholding ratio of Sunshine Industrial Development Co., Ltd. increased from approximately 8.06% to approximately 10.56%.

Alvogen is a global, privately held pharmaceutical company focused on developing, manufacturing and marketing generic, branded, over-the-counter (OTC) and biosimilar products for patients around the world. The company is passionate about improving people's lives by making quality medicines more accessible around the world. Alvogen has about 350 different medical and non-medical products. A powerful investment alliance of Aztiq and Innobic acquires Alvogen’s shares in Lotus and Adalvo in a US$475m deal.

HEC Pharm is one of the major players operating in the Tamiflu (Oseltamivir) Drug market, holding a share of 10.92% in 2022.

Segmentation Overview:

Refers to the different dosage forms of drugs are divided into Capsule, Oral Solution. In the Capsule type, the product is wrapped in a relatively stable casing. An oral solution is a medicine in liquid form for drinking. In this report, oral solutions include oral suspensions and granules that require infusion.

Among different product types, Capsule segment is anticipated to contribute the largest market share in 2027.

Application Overview:

Differentiate according to the treatment of the disease. Influenza A virus is an influenza virus comprising several subtypes that can infect a variety of mammals including wild birds, domesticated poultry, pigs, horses and humans and cause influenza.
Influenza B virus is an influenza virus belonging to the genus Influenza B virus of the family Orthomyxoviridae, which can cause influenza. Influenza B viruses only infect humans and pinnipeds.

The market's largest segment by application is the segment Influenza B, with a market share of 54.74% in 2021.

Key Companies in the global Tamiflu (Oseltamivir) Drug market covered in Chapter 3:

Hetero Group
Zydus Lifesciences
HEC Pharm
Teva Pharmaceuticals Limited
Roche
LUPIN Limited
Macleods Pharmaceuticals Limited
ALVOGEN

In Chapter 4 and Chapter 14.2, on the basis of types, the Tamiflu (Oseltamivir) Drug market from 2018 to 2029 is primarily split into:

Capsule
Oral Solution

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Tamiflu (Oseltamivir) Drug market from 2018 to 2029 covers:

Influenza A
Influenza B

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)